Loading…
Metrifonate Enhances the Ability of Alzheimer's Disease Patients to Initiate, Organize, and Execute Instrumental and Basic Activities of Daily Living
The objective of this analysis was to evaluate comprehensively the efficacy of metrifonate, a long-acting acetylcholinesterase inhibitor, in improving the ability of mild-to-moderate Alzheimer's disease (AD) patients to perform activities of daily living (ADLs). Alzheimer's disease patient...
Saved in:
| Published in: | Journal of geriatric psychiatry and neurology 2000-04, Vol.13 (1), p.9-16 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c426t-3835b1b95e09552eeece09376456a92cc7718a1088a5f2092ba19752d9f7b3103 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c426t-3835b1b95e09552eeece09376456a92cc7718a1088a5f2092ba19752d9f7b3103 |
| container_end_page | 16 |
| container_issue | 1 |
| container_start_page | 9 |
| container_title | Journal of geriatric psychiatry and neurology |
| container_volume | 13 |
| creator | Gélinas, Isabelle Gauthier, Serge Cyrus, PamelaA |
| description | The objective of this analysis was to evaluate comprehensively the efficacy of metrifonate, a long-acting acetylcholinesterase inhibitor, in improving the ability of mild-to-moderate Alzheimer's disease (AD) patients to perform activities of daily living (ADLs). Alzheimer's disease patients with Mini-Mental State Examination scores of 10 to 26 were enrolled in three 26-week trials to receive once-daily placebo (n = 430) or metrifonate 30 to 60 mg (by weight, n = 650) or 60/80 mg (by weight, n = 197). Metrifonate efficacy was assessed using the Disability Assessment for Dementia scale. Data from the three studies were pooled and analyzed retrospectively. The intent-to-treat analysis (last observation carried forward) at 26 weeks demonstrated that metrifonate significantly improved the ability of AD patients to perform ADLs when compared with placebo (30-60 mg dose, Δ = 3.03; P = .002; 60/80 mg dose, Δ = 5.25; P = .0002). Metrifonate significantly improved the ability of the AD patients to perform instrumental ADLs, those abilities typically lost first during the disease process (30-60 mg dose, Δ = 3.88, P = .002; 60/80 mg dose, Δ = 5.79, P = .003). Metrifonate also tended to improve, relative to placebo, the ability of AD patients to use three levels of executive skills when performing ADLs: initiation (30-60 mg dose, Δ = 3.45, P = .001; 60/80 mg dose, Δ = 5.44, P = .003), planning/organization (30-60 mg dose, Δ = 4.50, P = .004; 60/80 mg dose, Δ = 4.89, P = .014), and effective execution (30-60 mg dose, Δ = 1.80, P = .076; 60/80 mg dose, Δ = 4.06, P = .030). These results indicate that metrifonate has a beneficial effect on the ADLs in mild-to-moderate AD patients. ( J Geriatr Psychiatry Neurol 2000; 13:9-16). |
| doi_str_mv | 10.1177/089198870001300102 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21204527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_089198870001300102</sage_id><sourcerecordid>51600401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-3835b1b95e09552eeece09376456a92cc7718a1088a5f2092ba19752d9f7b3103</originalsourceid><addsrcrecordid>eNp9kc9uEzEQxi0EomnhBTggC6FyYan_xPHuMbQBIgWVA5xXs85s4mrX29peRPoevC8TEqkIJA6WR-Pf981YH2MvpHgnpbUXoqxkVZZWCCE1HaEesYk0RhXGivIxm-yBYk-csNOUbogzVamfshMprCGFmrCfnzFH3w4BMvJF2EJwmHjeIp83vvN5x4eWz7v7Lfoe45vEr3xCSMi_QPYYMrEDXwafPRm85ddxA8HfUwVhzRc_0I3kuwwpx7EnHLrfD-8hecfnLvvvpKSBNOQKfLfjK-qEzTP2pIUu4fPjfca-fVh8vfxUrK4_Li_nq8JN1SwXutSmkU1lUFT0bUR0VGk7m5oZVMo5a2UJUpQlmFaJSjUgK2vUumpto6XQZ-z84Hsbh7sRU657nxx2HQQcxlQrqcTUKEvgq7_Am2GMgXarlRZa2amVBKkD5OKQUsS2vo2-h7irpaj3idX_Jkail0fnselx_YfkEBEBr48AJAddGykinx44La0ShrCLA5Zggw_b_WfyL9ktqiA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230327471</pqid></control><display><type>article</type><title>Metrifonate Enhances the Ability of Alzheimer's Disease Patients to Initiate, Organize, and Execute Instrumental and Basic Activities of Daily Living</title><source>Sage Journals Online</source><creator>Gélinas, Isabelle ; Gauthier, Serge ; Cyrus, PamelaA</creator><creatorcontrib>Gélinas, Isabelle ; Gauthier, Serge ; Cyrus, PamelaA</creatorcontrib><description>The objective of this analysis was to evaluate comprehensively the efficacy of metrifonate, a long-acting acetylcholinesterase inhibitor, in improving the ability of mild-to-moderate Alzheimer's disease (AD) patients to perform activities of daily living (ADLs). Alzheimer's disease patients with Mini-Mental State Examination scores of 10 to 26 were enrolled in three 26-week trials to receive once-daily placebo (n = 430) or metrifonate 30 to 60 mg (by weight, n = 650) or 60/80 mg (by weight, n = 197). Metrifonate efficacy was assessed using the Disability Assessment for Dementia scale. Data from the three studies were pooled and analyzed retrospectively. The intent-to-treat analysis (last observation carried forward) at 26 weeks demonstrated that metrifonate significantly improved the ability of AD patients to perform ADLs when compared with placebo (30-60 mg dose, Δ = 3.03; P = .002; 60/80 mg dose, Δ = 5.25; P = .0002). Metrifonate significantly improved the ability of the AD patients to perform instrumental ADLs, those abilities typically lost first during the disease process (30-60 mg dose, Δ = 3.88, P = .002; 60/80 mg dose, Δ = 5.79, P = .003). Metrifonate also tended to improve, relative to placebo, the ability of AD patients to use three levels of executive skills when performing ADLs: initiation (30-60 mg dose, Δ = 3.45, P = .001; 60/80 mg dose, Δ = 5.44, P = .003), planning/organization (30-60 mg dose, Δ = 4.50, P = .004; 60/80 mg dose, Δ = 4.89, P = .014), and effective execution (30-60 mg dose, Δ = 1.80, P = .076; 60/80 mg dose, Δ = 4.06, P = .030). These results indicate that metrifonate has a beneficial effect on the ADLs in mild-to-moderate AD patients. ( J Geriatr Psychiatry Neurol 2000; 13:9-16).</description><identifier>ISSN: 0891-9887</identifier><identifier>EISSN: 1552-5708</identifier><identifier>DOI: 10.1177/089198870001300102</identifier><identifier>PMID: 10753002</identifier><identifier>CODEN: JGPNEN</identifier><language>eng</language><publisher>Thousand Oaks, CA: Sage Publications</publisher><subject>Activities of Daily Living - psychology ; Aged ; Aged, 80 and over ; Alzheimer Disease - diagnosis ; Alzheimer Disease - drug therapy ; Alzheimer Disease - psychology ; Biological and medical sciences ; Cholinesterase Inhibitors - administration & dosage ; Cholinesterase Inhibitors - adverse effects ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Double-Blind Method ; Female ; Humans ; Male ; Medical sciences ; Mental Status Schedule ; Neurology ; Neuropharmacology ; Pharmacology. Drug treatments ; Prospective Studies ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Treatment Outcome ; Trichlorfon - administration & dosage ; Trichlorfon - adverse effects</subject><ispartof>Journal of geriatric psychiatry and neurology, 2000-04, Vol.13 (1), p.9-16</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright Decker Periodicals, Inc. Spring 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-3835b1b95e09552eeece09376456a92cc7718a1088a5f2092ba19752d9f7b3103</citedby><cites>FETCH-LOGICAL-c426t-3835b1b95e09552eeece09376456a92cc7718a1088a5f2092ba19752d9f7b3103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1317205$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10753002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gélinas, Isabelle</creatorcontrib><creatorcontrib>Gauthier, Serge</creatorcontrib><creatorcontrib>Cyrus, PamelaA</creatorcontrib><title>Metrifonate Enhances the Ability of Alzheimer's Disease Patients to Initiate, Organize, and Execute Instrumental and Basic Activities of Daily Living</title><title>Journal of geriatric psychiatry and neurology</title><addtitle>J Geriatr Psychiatry Neurol</addtitle><description>The objective of this analysis was to evaluate comprehensively the efficacy of metrifonate, a long-acting acetylcholinesterase inhibitor, in improving the ability of mild-to-moderate Alzheimer's disease (AD) patients to perform activities of daily living (ADLs). Alzheimer's disease patients with Mini-Mental State Examination scores of 10 to 26 were enrolled in three 26-week trials to receive once-daily placebo (n = 430) or metrifonate 30 to 60 mg (by weight, n = 650) or 60/80 mg (by weight, n = 197). Metrifonate efficacy was assessed using the Disability Assessment for Dementia scale. Data from the three studies were pooled and analyzed retrospectively. The intent-to-treat analysis (last observation carried forward) at 26 weeks demonstrated that metrifonate significantly improved the ability of AD patients to perform ADLs when compared with placebo (30-60 mg dose, Δ = 3.03; P = .002; 60/80 mg dose, Δ = 5.25; P = .0002). Metrifonate significantly improved the ability of the AD patients to perform instrumental ADLs, those abilities typically lost first during the disease process (30-60 mg dose, Δ = 3.88, P = .002; 60/80 mg dose, Δ = 5.79, P = .003). Metrifonate also tended to improve, relative to placebo, the ability of AD patients to use three levels of executive skills when performing ADLs: initiation (30-60 mg dose, Δ = 3.45, P = .001; 60/80 mg dose, Δ = 5.44, P = .003), planning/organization (30-60 mg dose, Δ = 4.50, P = .004; 60/80 mg dose, Δ = 4.89, P = .014), and effective execution (30-60 mg dose, Δ = 1.80, P = .076; 60/80 mg dose, Δ = 4.06, P = .030). These results indicate that metrifonate has a beneficial effect on the ADLs in mild-to-moderate AD patients. ( J Geriatr Psychiatry Neurol 2000; 13:9-16).</description><subject>Activities of Daily Living - psychology</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - psychology</subject><subject>Biological and medical sciences</subject><subject>Cholinesterase Inhibitors - administration & dosage</subject><subject>Cholinesterase Inhibitors - adverse effects</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental Status Schedule</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Treatment Outcome</subject><subject>Trichlorfon - administration & dosage</subject><subject>Trichlorfon - adverse effects</subject><issn>0891-9887</issn><issn>1552-5708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNp9kc9uEzEQxi0EomnhBTggC6FyYan_xPHuMbQBIgWVA5xXs85s4mrX29peRPoevC8TEqkIJA6WR-Pf981YH2MvpHgnpbUXoqxkVZZWCCE1HaEesYk0RhXGivIxm-yBYk-csNOUbogzVamfshMprCGFmrCfnzFH3w4BMvJF2EJwmHjeIp83vvN5x4eWz7v7Lfoe45vEr3xCSMi_QPYYMrEDXwafPRm85ddxA8HfUwVhzRc_0I3kuwwpx7EnHLrfD-8hecfnLvvvpKSBNOQKfLfjK-qEzTP2pIUu4fPjfca-fVh8vfxUrK4_Li_nq8JN1SwXutSmkU1lUFT0bUR0VGk7m5oZVMo5a2UJUpQlmFaJSjUgK2vUumpto6XQZ-z84Hsbh7sRU657nxx2HQQcxlQrqcTUKEvgq7_Am2GMgXarlRZa2amVBKkD5OKQUsS2vo2-h7irpaj3idX_Jkail0fnselx_YfkEBEBr48AJAddGykinx44La0ShrCLA5Zggw_b_WfyL9ktqiA</recordid><startdate>200004</startdate><enddate>200004</enddate><creator>Gélinas, Isabelle</creator><creator>Gauthier, Serge</creator><creator>Cyrus, PamelaA</creator><general>Sage Publications</general><general>Decker</general><general>SAGE PUBLICATIONS, INC</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7TK</scope></search><sort><creationdate>200004</creationdate><title>Metrifonate Enhances the Ability of Alzheimer's Disease Patients to Initiate, Organize, and Execute Instrumental and Basic Activities of Daily Living</title><author>Gélinas, Isabelle ; Gauthier, Serge ; Cyrus, PamelaA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-3835b1b95e09552eeece09376456a92cc7718a1088a5f2092ba19752d9f7b3103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Activities of Daily Living - psychology</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - psychology</topic><topic>Biological and medical sciences</topic><topic>Cholinesterase Inhibitors - administration & dosage</topic><topic>Cholinesterase Inhibitors - adverse effects</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental Status Schedule</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Treatment Outcome</topic><topic>Trichlorfon - administration & dosage</topic><topic>Trichlorfon - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gélinas, Isabelle</creatorcontrib><creatorcontrib>Gauthier, Serge</creatorcontrib><creatorcontrib>Cyrus, PamelaA</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of geriatric psychiatry and neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gélinas, Isabelle</au><au>Gauthier, Serge</au><au>Cyrus, PamelaA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metrifonate Enhances the Ability of Alzheimer's Disease Patients to Initiate, Organize, and Execute Instrumental and Basic Activities of Daily Living</atitle><jtitle>Journal of geriatric psychiatry and neurology</jtitle><addtitle>J Geriatr Psychiatry Neurol</addtitle><date>2000-04</date><risdate>2000</risdate><volume>13</volume><issue>1</issue><spage>9</spage><epage>16</epage><pages>9-16</pages><issn>0891-9887</issn><eissn>1552-5708</eissn><coden>JGPNEN</coden><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><abstract>The objective of this analysis was to evaluate comprehensively the efficacy of metrifonate, a long-acting acetylcholinesterase inhibitor, in improving the ability of mild-to-moderate Alzheimer's disease (AD) patients to perform activities of daily living (ADLs). Alzheimer's disease patients with Mini-Mental State Examination scores of 10 to 26 were enrolled in three 26-week trials to receive once-daily placebo (n = 430) or metrifonate 30 to 60 mg (by weight, n = 650) or 60/80 mg (by weight, n = 197). Metrifonate efficacy was assessed using the Disability Assessment for Dementia scale. Data from the three studies were pooled and analyzed retrospectively. The intent-to-treat analysis (last observation carried forward) at 26 weeks demonstrated that metrifonate significantly improved the ability of AD patients to perform ADLs when compared with placebo (30-60 mg dose, Δ = 3.03; P = .002; 60/80 mg dose, Δ = 5.25; P = .0002). Metrifonate significantly improved the ability of the AD patients to perform instrumental ADLs, those abilities typically lost first during the disease process (30-60 mg dose, Δ = 3.88, P = .002; 60/80 mg dose, Δ = 5.79, P = .003). Metrifonate also tended to improve, relative to placebo, the ability of AD patients to use three levels of executive skills when performing ADLs: initiation (30-60 mg dose, Δ = 3.45, P = .001; 60/80 mg dose, Δ = 5.44, P = .003), planning/organization (30-60 mg dose, Δ = 4.50, P = .004; 60/80 mg dose, Δ = 4.89, P = .014), and effective execution (30-60 mg dose, Δ = 1.80, P = .076; 60/80 mg dose, Δ = 4.06, P = .030). These results indicate that metrifonate has a beneficial effect on the ADLs in mild-to-moderate AD patients. ( J Geriatr Psychiatry Neurol 2000; 13:9-16).</abstract><cop>Thousand Oaks, CA</cop><pub>Sage Publications</pub><pmid>10753002</pmid><doi>10.1177/089198870001300102</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-9887 |
| ispartof | Journal of geriatric psychiatry and neurology, 2000-04, Vol.13 (1), p.9-16 |
| issn | 0891-9887 1552-5708 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21204527 |
| source | Sage Journals Online |
| subjects | Activities of Daily Living - psychology Aged Aged, 80 and over Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Alzheimer Disease - psychology Biological and medical sciences Cholinesterase Inhibitors - administration & dosage Cholinesterase Inhibitors - adverse effects Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Double-Blind Method Female Humans Male Medical sciences Mental Status Schedule Neurology Neuropharmacology Pharmacology. Drug treatments Prospective Studies Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Treatment Outcome Trichlorfon - administration & dosage Trichlorfon - adverse effects |
| title | Metrifonate Enhances the Ability of Alzheimer's Disease Patients to Initiate, Organize, and Execute Instrumental and Basic Activities of Daily Living |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T00%3A25%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metrifonate%20Enhances%20the%20Ability%20of%20Alzheimer's%20Disease%20Patients%20to%20Initiate,%20Organize,%20and%20Execute%20Instrumental%20and%20Basic%20Activities%20of%20Daily%20Living&rft.jtitle=Journal%20of%20geriatric%20psychiatry%20and%20neurology&rft.au=G%C3%A9linas,%20Isabelle&rft.date=2000-04&rft.volume=13&rft.issue=1&rft.spage=9&rft.epage=16&rft.pages=9-16&rft.issn=0891-9887&rft.eissn=1552-5708&rft.coden=JGPNEN&rft_id=info:doi/10.1177/089198870001300102&rft_dat=%3Cproquest_cross%3E51600401%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c426t-3835b1b95e09552eeece09376456a92cc7718a1088a5f2092ba19752d9f7b3103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230327471&rft_id=info:pmid/10753002&rft_sage_id=10.1177_089198870001300102&rfr_iscdi=true |